Brokers Set Expectations for IQVIA’s Q4 Earnings (NYSE:IQV)

IQVIA Holdings Inc. (NYSE:IQV) – Stock analysts at William Blair upped their Q4 2024 EPS estimates for shares of IQVIA in a report issued on Wednesday, December 11th. William Blair analyst M. Smock now forecasts that the medical research company will post earnings per share of $2.83 for the quarter, up from their prior estimate of $2.82. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for IQVIA’s current full-year earnings is $10.18 per share. William Blair also issued estimates for IQVIA’s Q1 2025 earnings at $2.37 EPS.

Other equities analysts have also issued research reports about the company. Redburn Atlantic initiated coverage on IQVIA in a research note on Monday, October 14th. They set a “buy” rating and a $276.00 target price on the stock. Deutsche Bank Aktiengesellschaft lowered their price objective on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. TD Cowen reduced their target price on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Leerink Partners reaffirmed an “outperform” rating and set a $248.00 price target (down from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Finally, Evercore ISI cut their price objective on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Four equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $256.19.

IQVIA Stock Down 0.2 %

IQVIA stock opened at $196.64 on Monday. IQVIA has a twelve month low of $187.62 and a twelve month high of $261.73. The stock has a market cap of $35.69 billion, a P/E ratio of 25.81, a P/E/G ratio of 2.05 and a beta of 1.49. The company’s 50-day moving average price is $211.07 and its two-hundred day moving average price is $223.87. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.

Institutional Investors Weigh In On IQVIA

A number of large investors have recently modified their holdings of IQV. FMR LLC boosted its stake in shares of IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after purchasing an additional 804,963 shares in the last quarter. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in IQVIA in the third quarter valued at approximately $147,683,000. 1832 Asset Management L.P. grew its stake in shares of IQVIA by 472.3% during the second quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock worth $96,487,000 after buying an additional 376,595 shares during the last quarter. Renaissance Technologies LLC acquired a new position in shares of IQVIA during the second quarter worth $70,610,000. Finally, Impax Asset Management Group plc lifted its stake in shares of IQVIA by 19.3% in the 2nd quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company’s stock valued at $344,998,000 after acquiring an additional 264,555 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.